Search

Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant's IPO & More

BIO ROUNDUP: NOBEL PRIZES, DUCHENNE STEPS, GUARDANT'S IPO & MORE

Cancer immunotherapy is all the rage these days. The idea of harnessing the immune system to treat cancer has sparked billions of dollars...

 
 
 
Bio Roundup: Big Approvals, ICER Influence, Drug-Price Pushback & More

BIO ROUNDUP: BIG APPROVALS, ICER INFLUENCE, DRUG-PRICE PUSHBACK & MORE

We'll start the roundup this week with two drug approvals that came late last Friday. Both were landmarks for the companies receiving...

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

BIOGEN SETS $750,000 INITIAL PRICE FOR FIRST-EVER SPINAL ATROPHY DRUG

Patients with spinal muscular atrophy got some good news last week when the FDA approved nusinersen , making it the first marketed...

 
 
 
FDA Approves Nusinersen Drug To Treat Spinal Muscular Atrophy

FDA APPROVES NUSINERSEN DRUG TO TREAT SPINAL MUSCULAR ATROPHY

The United States Food and Drug Administration has recently approved Nusinersen drug to treat Spinal Muscular Atrophy.

Ionis, Biogen Make History With FDA Nod for Spine Disease Drug

IONIS, BIOGEN MAKE HISTORY WITH FDA NOD FOR SPINE DISEASE DRUG

Patients with spinal muscular atrophy got an early Christmas present on Friday. The FDA approved nusinersen , making the drug the first-ever...

 
 
 
New Data Show Biogen, Ionis Drug Might Help More With Rare Spine Disease

NEW DATA SHOW BIOGEN, IONIS DRUG MIGHT HELP MORE WITH RARE SPINE DISEASE

Up until this point, studies of an experimental drug from Biogen and Ionis Pharmaceuticals had focused on patients with the most severe...